Navigation Links
AC Nova Technologies Inc Announces Health Canada Approval of NutraPause
Date:11/19/2013

utritional supplements, if you are suffering from a medical condition, please consult your healthcare professional before use.

Contra-Indications: Women pregnant or lactating

About Menopause
Menopause is a normal, natural event. It marks the permanent end of fertility and is usually confirmed when a woman has not menstruated for 12 consecutive months. For American women this typically happens at between ages of 48 and 52 and sometimes it occurs before the age of 40 but when that happens it is referred to as “premature menopause”. Menopause is preceded by several years of a transition period referred to as the perimenopausal phase which often lasts about 4 years. Although menopausal symptoms may vary amongst women, many of these symptoms are often very disruptive to a women`s quality of life.

Menopause is associated with reduced functioning of the ovaries due to aging, resulting in lower levels of estrogens and other hormones such as testosterone. Changes in these hormones cause many symptoms of menopause, which may include hot flashes and night sweats. While menopause is natural, many women suffer for years with symptoms that also disrupt their sleep but at the same time they have not discussed treatment options for their symptoms with their doctor and or health care practitioner.

About AC Nova Technologies Inc (aka ÀTI Pharma`)
AC Nova Technologies Inc (aka ATI Pharma) is headquartered in Canada with the USA affiliate in Denver Colorado. AC Nova Technologies is the exclusive licensee of NUS’s patented platform technology. At ATI Pharma, we strive to bring to the public only evidence-based natural therapies that have been clinically shown to improve quality of life and/or delay the onset of a medical condition. We strive to set the standard for quality, safety and value in the licensing, development and manufacture of health care products. To learn more, please visit us at '/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Elsevier organizes label-free technologies conference
2. Ben-Gurion U. and Cincinnati Childrens Hospital to develop pediatric-specific medical technologies
3. Georgia Tech launches HomeLab to help companies evaluate home health technologies
4. Elinext Leverages Latest QR Code and NFC Technologies in Mobile App Development for Retailers, Manufacturers, Advertisers, and Real Estate Companies
5. Simplus Technologies Announces First Update on its Fear of Flying App for Turbulence Called Turbcast
6. The search for medical technologies abroad
7. Life Sciences Discovery Fund makes company grants in health-related technologies
8. Cavern Technologies Kansas City Data Center Continues Rapid Growth with Latest Data Center Expansion
9. Mary Newswanger, from FullPowerLove.com, was Recently Nationally Featured on ABC, NBC, Fox, & LA Daily News Regarding Planet Friendly Technologies
10. Pool Services Technologies is Expanding
11. Life Sciences Discovery Fund makes grants to commercialize health-related technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... (PRWEB) December 26, 2014 Yisrayl Hawkins, Pastor ... an open letter in light of the Ferguson, Missouri unrest. ... of civil unrest and explains why it has only increased. ... mankind was even created. He says there is a very ... Yisrayl also says there is a set of rules, or ...
(Date:12/26/2014)... Orlando, FL (PRWEB) December 26, 2014 ... visitor health insurance in the USA, announced today a ... to assist members in choosing the right plan for ... take the complexity out of the selection process when ... premiums by age group with only a few clicks. ...
(Date:12/25/2014)... The microscopy market is estimated to grow ... million by 2019. Optical microscopy is the largest ... product segment is expected to show the fastest ... on nanotechnology, technological advancements, and increasing federal support ... Get Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... , ( ) , , , ... N.J., Aug. 6 Smart Balance, Inc. (Nasdaq: SMBL ) today announced its ... of $58.2 million, an increase of 21.2% versus year ago, and earnings per share of ... The second quarter net sales increase versus 2008 was due to a 13% ...
... Lifestyle changes up the odds for Cubans, Puerto Ricans, Mexicans, ... Hispanics who move to the United States, the good life ... their risk for cancer by 40 percent. , Living the ... University of Miami Miller School of Medicine. , Of three ...
... , NASHVILLE, Tenn. and GLEN ... find that 76 percent of surveyed pharmacy directors say ... will have only one preferred biologic for all immune ... ulcerative colitis. According to the new Formulary Forum report ...
... , , REDWOOD CITY, ... ) today announced that Kim Popovits, Genomic Health,s Chief Executive Officer, ... in Boston, on Thursday, August 13 at 1:30 p.m. ET. , ... webcast of the presentation, visit the Investor Relations section of Genomic ...
... , , HOUSTON, ... first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a ... cancer. The disease-specific trial is being conducted under a Bellicum Investigational ... anticipates reporting initial results of the study in 2010. , ...
... KIBBUTZ SHAMIR, Israel, Aug. 6 Shamir Optical ... issue its second quarter of 2009 earnings results on Thursday, August 13(th), ... 11:00 A.M. EDT that morning. , , The ... live, please go to www.kcsa.com approximately five minutes ...
Cached Medicine News:Health News:Smart Balance Announces 2009 Second Quarter Results 2Health News:Smart Balance Announces 2009 Second Quarter Results 3Health News:Smart Balance Announces 2009 Second Quarter Results 4Health News:Smart Balance Announces 2009 Second Quarter Results 5Health News:Smart Balance Announces 2009 Second Quarter Results 6Health News:Smart Balance Announces 2009 Second Quarter Results 7Health News:Smart Balance Announces 2009 Second Quarter Results 8Health News:Smart Balance Announces 2009 Second Quarter Results 9Health News:Smart Balance Announces 2009 Second Quarter Results 10Health News:Living in U.S. May Raise Hispanics' Cancer Risk 2Health News:Living in U.S. May Raise Hispanics' Cancer Risk 3Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 2Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 3Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results 2
(Date:12/24/2014)... , Dec. 24, 2014  Commonwealth Cornerstone Group (CCG) ... Tax Credits transaction on Tuesday to help fund the expansion ... (PHN) in Sharon . ... Pennsylvania . It is the largest employer ... more than 150 people on staff. Currently, PHN ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
(Date:12/24/2014)... BEIJING , Dec. 24, 2014  The International Trade ... by ResMed (RMD) against BMC Medical. In a notice issued ... and found that ResMed,s patent on its humidifier was invalid. ... decision a "monumental win". "We are very excited with the ... the position that we have taken since the very beginning ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... 10 A recent national survey of 505 pharmacists found ... for a patient to seek treatment early to help shorten ... percent of pharmacists say most patients should purchase over-the-counter (OTC) ... while only 26 percent of their patients take this proactive ...
... Nov. 10 Reportlinker.com announces that a ... its catalogue. , Injectable Drug ... , http://www.reportlinker.com/p0158352/Injectable-Drug-Delivery-Market-Impact-and-Industry-Trends.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... grows, companies are increasingly looking towards the ...
Cached Medicine Technology:Pharmacists Report Patients do not Treat Cold and Flu Symptoms Early Enough, New Survey Shows 2Pharmacists Report Patients do not Treat Cold and Flu Symptoms Early Enough, New Survey Shows 3Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 2Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 3Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 4Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 5Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends 6
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
Medicine Products: